Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.71 - $4.0 $55,746 - $130,400
-32,600 Reduced 59.6%
22,100 $84,000
Q1 2024

May 15, 2024

BUY
$1.58 - $1.78 $77,104 - $86,864
48,800 Added 827.12%
54,700 $96,000
Q4 2023

Feb 14, 2024

SELL
$1.7 - $2.05 $8,160 - $9,840
-4,800 Reduced 44.86%
5,900 $10,000
Q3 2023

Nov 14, 2023

SELL
$2.01 - $2.07 $6,833 - $7,037
-3,400 Reduced 24.11%
10,700 $21,000
Q2 2023

Aug 14, 2023

BUY
$1.94 - $2.11 $10,476 - $11,394
5,400 Added 62.07%
14,100 $28,000
Q1 2023

May 15, 2023

SELL
$1.99 - $2.55 $7,363 - $9,435
-3,700 Reduced 29.84%
8,700 $17,000
Q4 2022

Feb 14, 2023

BUY
$1.86 - $25.8 $23,064 - $319,920
12,400 New
12,400 $29,000

Others Institutions Holding ABIO

About ARCA biopharma, Inc.


  • Ticker ABIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,410,100
  • Description
  • ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydr...
More about ABIO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.